
Abbott Laboratories ABT
$ 103.95
-0.86%
Annual report 2025
added 02-20-2026
Abbott Laboratories Gross Profit 2011-2026 | ABT
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Abbott Laboratories
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 18.7 B | 17.9 B | 15.1 B | 11.8 B | 11.7 B | 11 B | 11.8 B | 24.8 B | 23.3 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.8 B | 11 B | 16.2 B |
Quarterly Gross Profit Abbott Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.4 B | 4.23 B | 4.22 B | 3.89 B | 4.09 B | 3.95 B | 3.92 B | 3.74 B | 3.75 B | 3.45 B | 3.06 B | 2.75 B | 2.9 B | 2.88 B | 2.9 B | 2.6 B | 2.84 B | 2.76 B | 2.8 B | 2.66 B | 2.86 B | 2.63 B | 2.64 B | 2.35 B | 2.55 B | 2.42 B | 2.43 B | 2.48 B | 2.84 B | 2.58 B | 2.75 B | 2.72 B | 6.54 B | 5.84 B | 5.75 B | 5.18 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.54 B | 2.35 B | 3.4 B |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | ||
|
Medtronic PLC
MDT
|
19.6 B | $ 87.01 | -0.23 % | $ 112 B | ||
|
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | ||
|
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
21.8 M | $ 1.36 | 0.37 % | $ 21.9 M | ||
|
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | ||
|
LENSAR
LNSR
|
14.1 M | $ 5.6 | -7.74 % | $ 64.5 M | ||
|
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | ||
|
AxoGen
AXGN
|
167 M | $ 32.7 | 2.98 % | $ 1.51 B | ||
|
CONMED Corporation
CNMD
|
750 M | $ 37.03 | 1.09 % | $ 1.15 B | ||
|
Orthofix Medical
OFIX
|
566 M | $ 11.86 | -0.13 % | $ 470 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
50 M | $ 24.73 | 0.98 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M | ||
|
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
25.1 M | $ 0.73 | 7.63 % | $ 39.7 M | ||
|
Aethlon Medical
AEMD
|
1.36 M | $ 2.16 | -6.09 % | $ 3.37 M | ||
|
Penumbra
PEN
|
942 M | $ 335.02 | -0.17 % | $ 13 B | ||
|
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | ||
|
AdaptHealth Corp.
AHCO
|
89.3 M | $ 11.65 | 12.34 % | $ 1.57 B | ||
|
Myomo
MYO
|
26.9 M | $ 0.69 | -2.28 % | $ 28.9 M | ||
|
Insulet Corporation
PODD
|
1.94 B | $ 226.85 | -0.1 % | $ 16 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
-10.6 M | $ 2.36 | -3.28 % | $ 138 M | ||
|
Invacare Corporation
IVC
|
48.3 M | - | - | $ 24.7 M | ||
|
Profound Medical Corp.
PROF
|
4.38 M | $ 5.14 | -4.76 % | $ 180 M | ||
|
EDAP TMS S.A.
EDAP
|
26.6 M | $ 3.92 | 4.96 % | $ 146 M | ||
|
OrthoPediatrics Corp.
KIDS
|
173 M | $ 16.0 | -2.88 % | $ 375 M | ||
|
Outset Medical
OM
|
46.8 M | $ 3.55 | -1.94 % | $ 54 K | ||
|
Quanterix Corporation
QTRX
|
65 M | $ 3.76 | -4.57 % | $ 160 M | ||
|
Inspire Medical Systems
INSP
|
779 M | $ 52.18 | -0.06 % | $ 1.53 B | ||
|
Pulmonx Corporation
LUNG
|
67.1 M | $ 1.33 | -4.32 % | $ 54.1 M | ||
|
Cutera
CUTR
|
-12.7 M | - | -10.19 % | $ 1.99 M | ||
|
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | ||
|
Sintx Technologies
SINT
|
461 K | $ 2.57 | 0.78 % | $ 7.13 M | ||
|
InspireMD
NSPR
|
2.65 M | $ 1.79 | 2.87 % | $ 115 M | ||
|
Eargo
EAR
|
14.3 M | - | - | $ 10.2 M | ||
|
NuVasive
NUVA
|
865 M | - | - | $ 2.07 B | ||
|
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M |